最新ニュース Rallybio (NASDAQ:RLYB) 株価情報

RALLYBIO CORP

Rallybio

Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

Rallybio Corp

The United States and China have agreed to a 90-day truce in their ongoing trade dispute, significantly scaling back reciprocal tariffs and establishing a <a href="https://www.benzinga.com/government/regulations/25/05/45342343/us-stock-futures-rise-as-us-china-agree-to-90-day-tariff-pause-wider-earnings-growth-should-drive-more-balanced-market-performance-says-expert">structured negotiation framework</a>.
What Happened: According to market analysts, this shift has removed a major source of tail risk and could drive a broad-based rebound in risk assets, including U.S. equities, the dollar and altcoins.
Under the terms of the provisional agreement announced Monday, the U.S. will impose a 30% tariff on Chinese imports, comprising a 10% base tariff consistent with other trading partners and an additional 20% specifically targeting fentanyl-related concerns. 
However, officials hinted that the total tariff burden could decline to just 10% pending progress in fentanyl negotiations. 
On the Chinese side, tariffs on U.S. goods have been immediately reduced to 10%, and all non-tariff barriers, including rare earth export bans and aviation restrictions, have been lifted.
"This is a critical development," said Aurelie Barthere, Principal Research Analyst at Nansen. "It effectively removes the tail risk of sudden re-escalation during the agreed 90-day negotiation window." 
Barthere added that assets previously underperforming, such as altcoins, U.S. equities, and the dollar, now appear positioned for a catch-up rally. 
"Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) has been the clear outperformer so far… but with the latest Bessent and Greer announcements, I expect broader asset classes to begin catching up as the risk environment improves."
The tone of negotiations has also shifted. 
Treasury Secretary Scott Bessent emphasized a cooperative framework, noting that the two sides have "an established process, a mechanism, and clearly mandated negotiators," marking a contrast to the volatility of past talks. 
Both governments highlighted "common interests" and explicitly rejected the idea of economic decoupling.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45326605/vice-president-jd-vance-to-speak-at-bitcoin-2025-conference-in-las-vegas">Vice President JD Vance To Speak At Bitcoin 2025 Conference In Las Vegas</a>
Why It Matters: Markets responded swiftly. U.S. one-year yields rose nearly 10 basis points, suggesting a repricing of Federal Reserve expectations and reduced concerns over recession-linked rate cuts.
While tariffs on key sectors like autos and steel remain, experts suggest the ongoing negotiations may shift toward company-level solutions in sensitive areas such as semiconductors and pharmaceuticals.
From a digital asset perspective, the clearer macro picture is already impacting trading flows. 
Speaking with Benzinga, Charles d&#8217;Haussy, director at the DYDX Foundation, noted that "the market is moving past U.S.–China tariff worries," pointing to a renewed push toward deregulation and tax cuts. "Bitcoin has soared to $106,000… and derivatives markets are now targeting $125,000," he said, adding that Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) is also gaining momentum as a foundational layer for institutional tokenization efforts.
BlackRock's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NASDAQ">BLK</a>) recent meeting with the SEC to discuss Ethereum ETF staking underscores this pivot.
Rohan Misra, Head of GCC at AMINA Bank, added that current market behavior differs from the all-asset rally of 2021. 
"Only forfeited assets will be included in the U.S. digital asset stockpile. Digital assets with real-world use cases should see more traction as institutional momentum builds," he told Benzinga, while highlighting the central role of global macro factors in sustaining Bitcoin's leadership.
The truce agreement also includes a push by the U.S. to expand market access in China for U.S. goods and services, including agricultural exports, LNG and financial firms.
Currency manipulation was discussed but not emphasized, suggesting both sides aim to keep the negotiations focused on trade flows.
While uncertainty remains over whether risk assets can revisit their peak optimism levels from January, analysts agree the new framework reduces downside volatility.
"There is potential for risk assets to move beyond the January peak levels if we see a generous tax cut package materialize," Barthere said.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45322570/treasury-secretary-criticizes-senate-for-failing-to-advance-stablecoin-bill">Treasury Secretary Criticizes Senate For Failing To Advance Stablecoin Bill</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$ETH

Can The US-China Tariff De-Escalation Send Bitcoin, Ethereum To New Highs?

Barrington Research analyst Michael Petusky maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and raises the price target from $20 to $21.

Price Target

Analyst Ratings

XRAY

Barrington Research Maintains Outperform on Dentsply Sirona, Raises Price Target to $21

Speaking at the Daily Journal Annual Meeting in 2019, Charlie Munger, the late vice-chairman of Berkshire Hathaway Inc and Warren Buffett's longtime partner, stated in clear terms why their investment track record outperformed the rest. During his remarks, in his trademark humorous manner, he took a jibe at CNBC's Jim Cramer.
What Happened: Munger credited Berkshire Hathaway's success to doing less, not more. "We never had the illusion we could just hire a bunch of bright young people and they would know more than anybody about canned soup and aerospace and utilities," he <a href="https://www.youtube.com/watch?v=X1Oi3esiry8&amp;t=1201s">said</a>. "We never thought we could get really useful information on all subjects — like Jim Cramer tends to pretend to have."
Instead, Munger and Buffett stuck with a few key investments. "If we worked very hard, we could find a few things where we were right. And the few things were enough."
He shared that he bought Berkshire Hathaway stock in 1966 and made his first investment in Costco in 1997, holding onto both positions with <a href="https://www.benzinga.com/news/management/25/05/45248740/charlie-munger-says-the-secret-is-to-find-costcos-not-good-exits-saying-his-wealth-came-from-relentless-holding-and-not-slick-sell-signals">minimal selling over the years</a>.
"I don't like even looking for exits. I'm looking for holds," he said, adding "I practically never have a transaction. And the answer is: I'm right, and they're wrong."
See Also: <a href="https://www.benzinga.com/news/25/05/45314762/charlie-munger-was-once-asked-why-warren-buffett-was-so-much-richer-and-replied-he-got-an-earlier-start-before-adding-why-was-albert-einstein-poorer-than-i-was">Charlie Munger Was Once Asked Why Warren Buffett Was So Much Richer — He Replied, &#8216;He Got An Earlier Start,&#8217; Then Added, &#8216;Why Was Albert Einstein Poorer Than I Was?&#8217;</a>
Why It Matters: For Munger, the <a href="https://www.benzinga.com/markets/equities/25/04/44681817/charlie-munger-once-said-the-market-wont-do-exactly-what-you-want-when-you-want-as-tariff-jitters-and-wild-swings-remind-investors-why-long-term-thinking-matters">winning strategy was realism</a>, not hype. "My advice for a seeker of compound interest that works ideally is to reduce your expectations," he said, warning that future returns could be far lower than the historic 7% real gains from stocks. "It could well be three percent or two percent in real terms… and if that happens, I can have a happy life."
He urged investors not to chase unrealistic returns. "If it gets you 6% for a lifetime of work instead of five, you should be cheerful about it. You want to hit it out of the park easily — you should talk to Jim Cramer."
While Cramer has never publicly acknowledged Munger's taunts, in 2022, he said that Buffett and Munger were "<a href="https://www.youtube.com/watch?app=desktop&amp;v=Ct7A-FEh0S8">out of touch</a>" when it came to cryptocurrency, referring to their <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45280752/warren-buffetts-berkshire-delivered-a-16000-gain-since-listing-but-bitcoin-the-asset-he-called-rat-poison-turned-pennies-into-fortunes-faster">famous distaste</a> for it.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45342110/warren-buffetts-cash-mountain-grows-to-314-billion-as-berkshire-hathaway-emerges-as-top-treasury-bill-holder-wed-spend-100-billion-if-the-right-deal-came-along">Warren Buffett&#8217;s Cash Mountain Grows To $314 Billion As Berkshire Hathaway Emerges As Top Treasury-Bill Holder: &#8216;We&#8217;d Spend $100 Billion&#8217; If the Right Deal Came Along, Says Oracle Of Omaha</a></li>
</ul>
Image Via Shutterstock

Success Stories

General

Charlie Munger Once Mocked Jim Cramer For 'Pretending' To 'Know Everything' Then Explained Why Doing Less Made Him Billions

Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>), a trusted destination for pet parents and partners everywhere, announced today that the Company's Chief Financial Officer, David Reeder, will be departing in several months to return to the semiconductor industry as a Chief Executive Officer.
"We appreciate David's contributions during his time at Chewy and thank him for his leadership as we advanced our strategic, long-term growth initiatives," said Sumit Singh, Chief Executive Officer of Chewy. "As discussed on our March 26th earnings call, our long term plan remains intact, our business momentum remains strong, and we are reaffirming our guidance for the first quarter. David will remain as CFO through our next earnings announcement in June and assist with an orderly transition as we undertake a search for his successor. We wish David the very best as he prepares to return to the semiconductor industry, where he has spent much of his career in leadership positions."

Management

CHWY

Chewy CFO David Reeder To Depart, Transitioning To CEO Role in Semiconductor Sector; Reaffirms Q1 Guidance

Barrington Research analyst Kevin Steinke maintains HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) with a Outperform and lowers the price target from $16 to $13.

Barrington Research Maintains Outperform on HireQuest, Lowers Price Target to $13

Needham analyst Laura Martin reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and maintains $84 price target.

Reiteration

Needham Reiterates Buy on Trade Desk, Maintains $84 Price Target

K92 Mining (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KNT#TSX">KNT</a>) reported quarterly earnings of $0.29 per share. This is a 2800 percent increase over earnings of $0.01 per share from the same period last year. The company reported $144.60 million in sales this quarter. This is a 141.82 percent increase over sales of $59.80 million the same period last year.

Earnings

KNTNF

TSX:KNT

K92 Mining Q1 EPS $0.29 Up From $0.01 YoY, Sales $144.60M Up From $59.80M YoY

House Republicans unveiled plans for at least $880 billion in Medicaid cuts late Sunday as the cost-saving centerpiece to fund President Donald Trump&#8216;s $4.5 trillion tax break extension, igniting the largest healthcare battle since the 2017 Obamacare repeal attempt.
What Happened: The legislation, spanning hundreds of pages, would implement new work requirements and eligibility restrictions that Republicans frame as eliminating &#8220;waste, fraud and abuse&#8221; in safety net programs, <a href="https://apnews.com/article/medicaid-cuts-trump-tax-cuts-bill-1e2b12a91a3d12ceb0420ce7053de58e">reported</a> to the Associated Press. 
A Congressional Budget Office (CBO) preliminary analysis estimates 8.6 million Americans could lose healthcare coverage over the next decade.
&#8220;Savings like these allow us to use this bill to renew the Trump tax cuts and keep Republicans&#8217; promise to hardworking middle-class families,&#8221; said Rep. Brett Guthrie (R-KY), chairman of the Energy and Commerce Committee which oversees healthcare spending.
Democrats immediately denounced the proposal. &#8220;In no uncertain terms, millions of Americans will lose their health care coverage,&#8221; said Rep. Frank Pallone (D-NJ), the committee&#8217;s ranking Democrat. &#8220;Hospitals will close, seniors will not be able to access the care they need, and premiums will rise for millions of people if this bill passes.&#8221;
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45342343/us-stock-futures-rise-as-us-china-agree-to-90-day-tariff-pause-wider-earnings-growth-should-drive-more-balanced-market-performance-says-expert">US Stock Futures Rise As US, China Agree To 90-Day Tariff Pause: &#8216;Wider Earnings Growth Should Drive More Balanced Market Performance,&#8217; Says Expert</a>
Why It Matters: Meanwhile, Democrats have proposed an alternative approach, targeting Medicare Advantage &#8220;upcoding&#8221; practices. Over 40 Democratic lawmakers recently wrote to Republican leadership citing reports that <a href="https://www.benzinga.com/general/health-care/25/05/45313228/democrats-urge-gop-to-target-medicare-advantage-upcoding-instead-of-medicaid-cuts-calling-budget-plan-a-man-made-disaster">Medicare overpaid private insurers by $50 billion in 2024</a> for unverified diagnoses, representing $83 billion in excess payments compared to traditional Medicare.
State budgets are also at risk, with <a href="https://www.benzinga.com/news/25/03/44304047/mark-cuban-warns-nebraska-will-get-crushed-by-tariffs-and-medicaid-cuts-faces-a-200m-shortfall-this-year">Nebraska already facing a $200 million shortfall</a> even before potential Medicaid funding reductions, according to reports cited by entrepreneur Mark Cuban. Combined with recent tariff increases affecting agricultural exports, states heavily dependent on both federal healthcare funding and international trade could face compounded fiscal challenges.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45342325/first-american-pope-leo-xiv-calls-artificial-intelligence-another-industrial-revolution">First American Pope Leo XIV Calls Artificial Intelligence Another Industrial Revolution</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Health Care

House Republicans Push $880 Billion Medicaid Cuts To Renew Trump Tax Breaks—Democrat Warns: 'Millions Will Lose Their Health Care'

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and lowers the price target from $20 to $19.

ANIK

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $19

Wellgistics Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>, "Wellgistics Health")), a healthcare infrastructure and pharmaceutical distribution company leveraging proprietary technology, today announced financial results for its first fiscal quarter ended March 31, 2025.
Revenue for the Q1 2025 quarter increased to $10.86 million from zero during the comparable period last year on a GAAP basis. Had the Company acquired Wood Sage and Wellgistics LLC as of January 1, 2024, the $10.86 revenue figure of Q1 2025 would be compared to $7.97 million on a pro forma basis for the same period in 2024, representing approximately a 36% year-over-year increase on a non-GAAP basis.
Wellgistics Health expects continued momentum in Q2, supported by expanded clinical fulfillment capacity, new manufacturer integrations, and scaled deployment of its pharmacy hub platform.
 &nbsp;

WGRX

Wellgistics Health Posts $10.86M Q1 Revenue, Up 36% YoY On Pro Forma Basis

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) stocks are trading higher on Monday following a major de-escalation in the ongoing U.S.-China trade war.
What Happened: The company's stock gained over 3.21% in Pre-market trading on Monday morning after U.S. Treasury Secretary Scott Bessent announced both sides will reduce tariffs by over 115% for 90 days following negotiations.
U.S. goods will be subjected to a 10% tariff in China, while Chinese imports into the U.S. will face a 30% tariff. Interestingly, China's CCP had prohibited its airlines from importing Boeing planes and <a href="https://www.benzinga.com/25/04/44888512/boeing-jet-returns-to-us-amid-escalating-tariff-tensions-with-china">had sent back</a> the planes following escalating tensions.
Elsewhere, U.S. President Donald Trump also accepted a <a href="https://www.benzinga.com/25/05/45340930/trumps-400-million-boeing-jet-gift-from-qatar-sparks-outcry-from-larry-summers-peter-schiff-banana-republic-level-corruption">$400 million Boeing 747-8 Jumbo Jet</a> from the Qatari royal family, which sparked outrage among experts.
Price Action: Boeing shares were up 3.21% at $201.10 at the time of publication on Wednesday, according to<a href="http://pro.benzinga.com"> Benzinga Pro</a> data.
Photo by BlueBarronPhoto via Shutterstock

Equities

Movers & Shakers

Pre-Market Outlook

Markets

Tech

Boeing Stock Gains Over 3% In Monday Premarket: What's Going On?

HC Wainwright &amp; Co. analyst Andrew Fein maintains Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and lowers the price target from $72 to $68.

HC Wainwright & Co. Maintains Buy on Avidity Biosciences, Lowers Price Target to $68

Mark Zuckerberg may be renowned for creating Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) owned Facebook and shaping the internet as we know it today, but at home, he is like any father trying to ground his daughters in values, family, and reflection. In a podcast, he talked about a bedtime ritual he practices with his daughters, Max and August, which he calls "The Good Night Things."
What Happened: "Every night when I put my daughters to bed, we go through this thing and, like, they call it ‘the good night things,'" Zuckerberg explained <a href="https://www.youtube.com/watch?v=Gf1wzhRnkrc">on</a> the Lex Fridman podcast.
The ritual includes a conversation about four core values that Zuckerberg wants to instill in his children: health, relationships, excitement for the future, and kindness. "What do I want them to remember and just have really ingrained in them as they grow up?" he reflected.
The nightly list starts with health: "Making sure that you take care of yourself and keep yourself in good shape." The second is loving friends and family, which Zuckerberg says is "perhaps one of the most important things." The third something that they are excited about for the future. "I think the way we navigate [life] is that we have things that we&#8217;re looking forward to," he said.
And finally, each night ends with the question: "What did you do today to help someone?" "It can be as simple as, ‘I helped set the table for lunch,'" he said. "But that's sort of like&#8230; if you were to boil down my overall life philosophy into what I try to impart to my kids, those are the things that I think are really important."
See Also: <a href="https://www.benzinga.com/markets/25/05/45286464/bill-gates-commits-99-of-his-remaining-fortune-to-gates-foundation-set-to-wind-down-in-20-years-somebody-should-give-more-money-than-i-did">Bill Gates Commits 99% Of His Remaining Fortune To Gates Foundation, Set To Wind Down In 20 Years: &#8216;Somebody Should&#8230;Give More Money Than I Did&#8217;</a>
Why It Matters: Zuckerberg has presented himself as a ‘family man' in various media appearances over the years. Last year, he shared via Instagram that he was <a href="https://www.benzinga.com/personal-finance/25/04/45124694/mark-zuckerberg-says-his-wife-wanted-a-minivan-so-he-designed-a-porsche-hes-pretty-sure-should-exist-and-made-it-a-his-and-hers-set">designing a custom Porsche</a> as a special gift for his wife, Priscilla Chan. 
Describing it as a "new side quest," he revealed that the entire redesign was rooted in her preferences. Earlier in the same year, he <a href="https://www.benzinga.com/personal-finance/25/05/45241490/thats-weird-mark-zuckerberg-gifted-his-wife-a-7-foot-tall-turquoise-statue-of-herself-but-says-i-dont-think-she-was-that-happy-with-it">commissioned a marble statue of Chan</a>, posting a photo on Instagram with the caption: &#8220;Bringing back the Roman tradition of making sculptures of your wife.&#8221;
Despite these public expressions of family values and teaching his daughters about the importance of compassion for fellow human beings, Zuckerberg and Meta have faced repeated scrutiny for questionable business practices, such as measures undertaken to <a href="https://www.benzinga.com/general/social-media/25/03/44363736/zuckerbergs-global-push-meta-faces-scrutiny-over-privacy-free-speech-regulatory-tactics">infiltrate the Chinese market and employing lobbying tactics</a> in India; allegedly silencing ex-employees speaking out about issues like the company&#8217;s <a href="https://www.benzinga.com/25/03/44447618/facebook-whistleblower-says-mark-zuckerberg-led-metas-gag-order-is-silencing-her-from-speaking-to-congress-about-china-ties-teen-harm-and-harassment-claims">connections to China, harming teen users, and workplace misconduct</a> and <a href="https://www.benzinga.com/25/02/43723246/meta-faces-backlash-as-laid-off-workers-say-they-were-unfairly-targeted-despite-strong-performance-records">unfairly laying off workers</a> despite strong track records.  
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45338301/zuckerberg-foresees-tech-industry-revolution-with-ai-an-ai-that-can-effectively-be-a-sort-of-midlevel-engineer">Zuckerberg Foresees Tech Industry Revolution With AI: &#8216;An AI That Can Effectively Be a Sort of Midlevel Engineer&#8217;</a></li>
</ul>
Image Via Shutterstock

Social Media

Mark Zuckerberg's Bedtime Ritual With Daughters Max And August Reveals The Four Values He Wants To Pass Down—And Why He Calls It 'The Good Night Things'

HUB Cyber Security Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) ("HUB" or the "Company"), a developer of confidential computing cybersecurity solutions and services, today announced a series of new customer wins through its cybersecurity division, further expanding its footprint in high-risk, regulated industries including healthcare, financial services, and digital infrastructure.
The new engagements, signed over the first quarter of 2025 and collectively valued at over $1.5 million, underscore HUB's continued momentum in providing secured, compliant infrastructure to organizations facing increasingly complex data protection and regulatory challenges.

HUBC

HUB Cyber Security Lands $1.5M in New Contracts, Expanding in Healthcare and Financial Sectors

Imperial Metals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/III#TSX">III</a>) reported quarterly earnings of $0.26 per share. This is a 533.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported $176.62 million in sales this quarter. This is a 108.85 percent increase over sales of $84.57 million the same period last year.

TSX:III

Imperial Metals Q1 Adj. EPS $0.26 Up From $(0.06) YoY, Sales $176.62M Up From $84.57M YoY

Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) sees Q2 sales of $100.000 million-$102.000 million vs $114.61 million analyst estimate.

Guidance

CHGG

Chegg Sees Q2 Sales $100.000M-$102.000M vs $114.61M Est

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk&#8216;s stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.
What Happened:&nbsp;Cuban criticized Kirk&#8217;s&nbsp;focus on Big Pharma as&nbsp;the primary driver of high drug prices. Instead, Cuban pointed to PBMs as the major offenders&nbsp;due to their opaque pricing&nbsp;practices and market dominance. Cuban highlighted the lack of transparency in PBMs&#8217; contracts, which often prohibit disclosing pricing details. He challenged&nbsp;Kirk to obtain a net&nbsp;price list from his company&#8217;s PBM. 
Meanwhile, Charlie Kirk, the founder of Turning Point USA, has regularly raised questions on the practices of Big Pharma through his posts and podcasts.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Charlie , you aren&#39;t close. Drug prices are too damn high. But the big culprit isn&#39;t the brand manufacturers, it&#39;s the big middlemen. Namely PBMs. They work so hard to distort pricing the first lines in their contracts with everyone is &quot;you can&#39;t disclose any of this &quot; How bad… <a href="https://t.co/oMnlvlOPtl">https://t.co/oMnlvlOPtl</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1921755430708969767?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban&#8217;s post aligns&nbsp;with a 2022 FTC investigation&nbsp;into PBMs&#8217;&nbsp;role in rising drug costs&nbsp;through practices like spread pricing. Moreover, according to a 2023 Bipartisan&nbsp;Policy Center, six PBMs control&nbsp;95% of the private market. 
He supports Trump's Executive Order to lower drug prices by 30-80%, suggesting that targeting PBMs, such as separating formularies and mandating claim disclosures, could make brand medications cheaper than in many countries, building on his own efforts with Cost Plus Drugs to cut out middlemen and reduce costs.
In one of his initial responses, Mark Cuban expressed support for the move, stating it could &#8220;force transparency,&#8221; even if the President can&#8217;t mandate price reductions.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/05/45338281/trump-has-a-proven-track-record-of-being-an-absolute-failure-says-gov-tim-walz-we-dont-need-to-run-governmen" target="_blank" rel="noreferrer noopener">Trump Has A &#8216;Proven Track Record Of Being An Absolute Failure,&#8217; Says Gov. Tim Walz—&#8217;We Don&#8217;t Need To Run Government Like A Business&#8217;</a>
Why It Matters: Cuban&#8217;s comments come in the wake of President Donald Trump&#8216;s announcement of a sweeping executive order aimed at slashing prescription drug prices. The order, which Trump referred to as the &#8220;most consequential executive order&#8221; in U.S. history, is set to implement a &#8220;Most Favored Nations&#8221; <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">policy requiring</a> pharmaceutical companies to charge U.S. consumers no more than the lowest price they offer for the same drug in any other country.
Cuban, despite being a Trump critic, has <a href="https://benzinga.com/markets/25/04/44866755/mark-cuban-says-this-trump-healthcare-order-could-save-hundreds-of-billions">expressed support</a> for Trump&#8217;s healthcare order, emphasizing its potential to reform the role of PBMs in the U.S. healthcare system and save billions. He believes&nbsp;that targeting PBMs—such as separating&nbsp;formularies and mandating claim disclosures—could&nbsp;make brand medications cheaper than&nbsp;in many countries.
Meanwhile, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) were trading 2% to 5% lower in Monday&#8217;s premarket in response to Trump&#8217;s executive order.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45328061/bitcoin-ethereum-xrp-dogecoin-enter-weekend-strong-long-dips-140000-is-programmed-trader-says" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Enter Weekend Strong: &#8216;Long Dips, $140,000 Is Programmed,&#8217; Trader Says &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company…Ask Your PBM For A List Of Claims'

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) reported quarterly losses of $(0.06) per share. This is a 123.08 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $121.39 million which beat the analyst consensus estimate of $114.61 million by 5.92 percent. This is a 30.38 percent decrease over sales of $174.35 million the same period last year.

Earnings Beats

Chegg Q1 Adj. EPS $(0.06) Down From $0.26 YoY, Sales $121.39M Beat $114.61M Estimate

– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints –
– MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring –
– bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms –
MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:<a href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) were featured at the 2025 International MSA Congress. The Congress was presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational resources, research funding, and community engagement.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Alterity Therapeutics Presents MSA Research At 2025 International MSA Congress; ATH434 Phase 2 Data Shows Clinically Meaningful Efficacy On Multiple Clinical Endpoints

Comments

Rallybio

ニュース

最新ニュース Rallybio (NASDAQ:RLYB) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル